45 results about "Catecholaminergic" patented technology

Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.

The invention discloses a multicolor non-toxic hair dye and a preparation method and dying method thereof. The multicolor non-toxic hair dye is characterized by comprising an A agent and a B agent, wherein the A agent comprises catecholamine or a catecholamine derivative, a thickening agent, a pH-regulating agent, a pigment additive and water; and the B agent comprises an oxidizer, a thickening agent, a pH-regulating agent and water. The catecholamines substances are adopted and oxidized by the oxidizer, so that melanin analogues high in surface adhesion properties are formed, and are coated to the surface of hair in an in situ manner, and the surface color of hair can be changed. Compared with a conventional hair dye, the hair dye disclosed by the invention is free from toxin, and betterin biological safety. The hair dye is high in dying stability, low in cost, simple in preparation technology and favorable for environment prevention, can well meet color diversity requirements, doesnot need to be heated when being used, can be applied to the surface of the hair after the A agent and the B agent are uniformly mixed, and is simple to operate during dying, short in dying time, andwidely applied to various crowds.

The present invention provides novel compounds of Formula Iand salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

The present invention provides novel compounds of Formula Iand salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

The present invention relates to novel 3-phenyl-azetidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-azetidine derivatives of the invention and to the use of these compounds for therapeutic applications.

The microcapsule adrenomedullary cell for curing malignant tumor pain consists of ACA microcapsule or APA microcapsule embedded human or animal adrenomedullary cell and the microcapsule entrapped molecular weight is 68-97.4 KD. The microcapsule adrenomedullary cell for curing malignant tumor pain is prepared through five steps of: separation of adrenomedullary cell from human or animal adrenal gland, short period culture in culture liquid, microencapsulation of adrenomedullary cell with ACA or APA, freeze storing in liquid nitrogen and restoring temperature in 37 deg.C before use. The microcapsule adrenomedullary cell for curing malignant tumor pain is transplanted to under human arachnoid of tumor patient to produce obvious pain relieving effect and immune isolation.

The invention provides a screening kit for malignant arrhythmia, an establishing method and an application of the animal model. In the method one RyR2 mutation site (p. A690E) is detected in patient families with familial sudden cardiac death history and confirmed. A transgenic animal model is further applied, and a gene knock-in mouse is successfully built. The phenotype of sudden death and ventricular tachycardia induced by the mutation is verified by the mouse model, and the effects of mutation on the structure and function of calcium channel are further investigated by biochemistry, electrophysiology, cell and structural biology, disclosing the molecular mechanism of catecholaminergic polymorphic ventricular tachycardia (CPVT) induced by mutation. The method provides a new idea for thetreatment of CPVT and the prevention of sudden death, and can be applied to the mouse model to screen the arrhythmia treatment drugs.

The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and salts thereofThe compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.The invention also relates to new intermediates of said process.

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the specification, or a salt thereof.

A catecholamine or related compound having (S)-configuration at β-carbon, a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof and having a lipophilicity greater than (S)-noradrenaline has use as an anti-angiogenic agent. A catecholamine or related compound in which a β-hydroxy group has been modified are also anti-angiogenic. The anti-angiogenic agent is preferably a compound of formula (I) or (II)a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof.

The present invention concerns a method for the treatment of recessive Catecholaminergic Polymorphic Ventricular Tachycardia comprising delivering a gene into a cardiac cell.

The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and pharmaceutically acceptable salts thereofThe compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.The invention also relates to a new intermediate of said process.